Cell therapy for blood vessel inflammation
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new cell therapy called CT1192 for people with ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. The therapy aims to reset the immune system to stop the disease, and this early study focuses on safety and how the cells work in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have a confirmed diagnosis of ANCA-associated vasculitis (like microscopic polyangiitis, granulomatosis with polyangiitis, or eosinophilic granulomatosis with polyangiitis).
- Your vasculitis must still be active despite at least 6 months of standard treatment (steroids plus immunosuppressants).
- Your kidneys, liver, bone marrow, heart, and lungs must be working reasonably well (your doctor will check this).
- You cannot have had certain treatments like rituximab in the last 6 months, or any CAR-T therapy before.
- Women who can get pregnant and men with partners who can get pregnant must agree to use effective birth control for up to a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
This trial is testing a new type of cell therapy called universal CAR-T cells combined with immunosuppressant drugs for people with hard-to-treat autoimmune diseases. The goal is to see if this approach is safe and can help reduce disease activity.
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.